Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Author:
Funder
Eli Lilly and Company
Publisher
Elsevier BV
Subject
General Medicine
Reference32 articles.
1. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetes Care,2022
2. Mechanisms linking obesity to insulin resistance and type 2 diabetes;Kahn;Nature,2006
3. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation;Lingvay;Lancet,2022
4. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes;Frías;N Engl J Med,2021
5. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial;Frias;Lancet,2018
Cited by 132 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity;Current Diabetes Reviews;2024-10
2. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13
3. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis;Indian Journal of Endocrinology and Metabolism;2024-09-04
4. Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023;Diabetes, Obesity and Metabolism;2024-09-02
5. Effects of Once-Weekly Subcutaneous Retatrutide on Weight and Metabolic Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Metabolism Open;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3